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Procoagulant factors and the risk of
myocardial infarction in young women
Elevated levels of coagulation factor VIII, IX and
XI are associated with an increased risk of venous
thrombosis (1–7). The role of factor VIII, IX and
XI in the pathogenesis of myocardial disease is less
clear, although associations between risk factors for
cardiovascular disease, i.e. age, hyperlipidaemia,
high blood pressure, diabetes, obesity, menopausal
status and social class, and elevated factor VIII or
IX levels have been described (8–11).
Blood group and von Willebrand factor (VWF)
are important determinants of factor VIII levels.
Lower levels of factor VIII and VWF are present in
subjects with blood group O compared with those
with blood group A, B or AB. Elevated factor VIII
levels have been associated with ischaemic heart
disease in men (12–14).
For VWF, the main determinants are ABO blood
group, age (15, 16), acute-phase reaction and
endothelial dysfunction (17, 18). Some evidence
for the role of factor VIII and VWF in cardiovas-
cular disease was found in cohort studies (19–22).
Moreover, patients with factor VIII and IX deﬁci-
ency (haemophilia A and B) are protected against
ischaemic heart disease (23, 24).
Elevated levels of VWF and factor VIII may also
be the result of endothelial damage, i.e. be markers
for existing atherosclerosis. C-reactive protein
(CRP) is a sensitive marker for underlying systemic
inﬂammation and acute-phase reaction, and may be
used to investigate the role of an acute-phase
response in bringing about increased factor VIII
and VWF levels. In postmenopausal women, CRP
was found to be a strong risk factor for cardiovas-
cular events (25), but virtually no data are available
in premenopausal women. In men, CRP predicts
risk with elevations that can largely be explained by
more conventional risk factors (26, 27).
Factor XI and IX are zymogens of serine
proteases and are converted to active enzymes
during blood coagulation. Factor IX belongs with
factor X, VII and prothrombin to the vitamin K-
dependent factors, which require vitamin K for
their complete synthesis. Factor XI, IX and VIII
are required for continued thrombin generation
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Abstract: Objectives: We investigated whether elevated levels of factor
VIII, IX and XI is associated with myocardial infarction (MI) in young
women. In addition, we studied ABO blood group, von Willebrand
factor (VWF) and C-reactive protein (CRP). Methods and
results: We compared 200 women with MI before age 49 years with
626 controls from a population-based case–control study. Mean levels of
factor VIII activity (VIII), von Willebrand factor antigen (VWF), factor
IX activity (IX) were higher in patients (133, 134 and 132 IU/dL) than in
controls (111, 107 and 120 IU/dL, respectively). Mean levels of factor
XI (XI) were equal in patients (114 IU/dL) and controls (113 IU/dL).
The odds ratio (OR) for MI for blood group non-O vs. O was 1.6 [95%
conﬁdence interval (CI) 1.1–2.3]. The OR adjusted for age, index year
and area of residence for the highest quartile >150 IU/dL of factor VIII
was 2.7 (95% CI 1.6–4.6), of VWF 4.7 (95% CI 2.3–9.7), of factor IX 2.6
(95% CI 1.3–5.4) and of factor XI 0.9 (95% CI 0.5–1.4), all compared
with the lowest quartile <100 IU/dL. Conclusions: Non-O blood
group, high VWF, factor VIII and factor IX levels are associated with an
increased risk ofMI in young women, while high factor XI levels are not.
Bea Tanis1, Ale Algra2,3,5, Yolanda
van der Graaf2, Frans Helmerhorst4,
Frits Rosendaal5
1Department of Haematology, Leiden University Medical
Centre, Leiden; 2Julius Centre for Health Sciences and
Primary Care, Utrecht University Medical Centre,
Utrecht; 3Department of Neurology, Utrecht University
Medical Centre, Utrecht; Departments of 4Gynaecology
and Reproductive Medicine, and 5Clinical Epidemiology,
Leiden University Medical Centre, Leiden, the
Netherlands
Key words: case–control study; coagulation factors;
myocardial infarction; risk factor; women
Correspondence: Prof. Dr F.R. Rosendaal, Department of
Clinical Epidemiology, Leiden University Medical Centre,
C9-P, PO Box 2600, 2300 RC Leiden, the Netherlands
Tel: 0031 71 5264037
Fax: 0031 71 5266994
e-mail: f.r.rosendaal@lumc.nl
Accepted for publication 30 January 2006
Eur J Haematol 2006: 77: 67–73
doi:10.1111/j.1600-0609.2006.00656.x
All rights reserved
 2006 The Authors
Journal compilation  2006 Blackwell Munksgaard
EUROPEAN JOURNAL OF HAEMATOLOGY
67
and maintenance of ﬁbrin formation (28). After the
activation of factor XI by thrombin, additional
thrombin formation takes place inside the ﬁbrin
clot via the intrinsic pathway (29). The role of
factor XI in haemostasis can be seen as a combi-
nation of procoagulant and antiﬁbrinolytic actions
(30).
In the present study, we investigated the associ-
ation between elevated factor VIII, IX and XI
activity and the risk of myocardial infarction (MI)
in young women. In this speciﬁc patient group,
arterial thrombosis is presumed to play a more
important role than in older patients who have
relatively more atherosclerosis and longer exposure
to major cardiovascular risk factors. To investigate
the mechanisms of genetic and acquired factors that
inﬂuence coagulation factors, we also determined
the role of blood group, VWF, CRP and ﬁbrinogen
on the risk of MI.
Patients and methods
Design
The study design of this population-based case–
control study on acute MI in young women in
the Netherlands, the Risk of Arterial Thrombosis
In relation with Oral contraceptive use (RATIO)
study, has been described in detail previously
(31). In summary, we included 248 patients with
a ﬁrst acute MI between 18 and 49 yr of age,
who were selected from university and regional
hospitals in the period January 1990 to October
1995. Controls consisted of 925 women, contacted
by random-digit dialling, stratiﬁed for age, index
year of MI and area of residence. All consenting
patients and control women completed a stan-
dardized mail questionnaire on demographics,
oral contraceptive use, history of hypertension,
diabetes and hypercholesterolaemia, cigarette
smoking, alcohol, height and weight, and family
history of cardiovascular disease. Women were
classiﬁed as hypertensive, diabetic or hypercho-
lesterolaemic when they reported a physician’s
diagnosis or were taking medication for these
conditions before the index date. Body mass
index (BMI) was calculated as body weight (kg)
divided by height squared (m2). We considered as
obese any woman with a BMI ‡ 27.3 kg/m2.
Women were classiﬁed as current smokers when
they reported smoking in the year before the
index date. A family history of cardiovascular
disease was deﬁned as the presence of MI, stroke
or peripheral arterial disease in one or both
parents before 60 yr of age. For the analyses of
factor IX levels, patients on oral anticoagulant
medication were excluded (n ¼ 21).
Blood collection and plasma assays
We obtained blood samples for measurement of
coagulation factors from 200 patients and 626
control women with a mean interval of 5 yr after
the index date for cases and controls. Blood was
collected from the antecubital vein into tubes
containing 0.1 volume 0.106 mol/L trisodium
citrate. Plasma was prepared by centrifugation
for 10 min at 2000 g at room temperature and
stored at )70C, until use. ABO blood groups
were determined by routine serum blood-grouping
procedures. Factor VIII activity (VIII), factor IX
activity (IX) and factor XI activity (XI) levels
were measured by a one-stage clotting assay with
factor VIII-, factor IX- and factor XI-deﬁcient
plasma, respectively, and automated activated
partial thromboplastin time (APTT; Organon
Teknika, Boxtel, the Netherlands) on a STA
(Diagnostica Stago, Boehringer Mannheim).
VWF antigen (VWF) was measured by an
enzyme-linked immunosorbent assay (ELISA),
using polyclonal antibodies (Dako, High Wyco-
mbe, UK). All measurements were performed in
duplicate in two diﬀerent dilutions, with a coef-
ﬁcient of variation <10%. Plasma levels were
expressed as units per decilitre (IU/dL). By
deﬁnition, 1 dL pooled normal plasma contains
100 units. Fibrinogen was determined according
to Von Clauss using the reagents of Behringwerke
AG (Marburg, Germany). CRP levels were
measured by an enzyme immunoassay (CRP
EAI HS, Kordia, Leiden, the Netherlands).
Plasma CRP concentration of 10 mg/L and above
was classiﬁed as ‡10 mg/L. The technician was
unaware of whether samples were from patients
or control women. The study protocol was
approved by the Ethical Committees of all
participating hospitals and all women gave
informed consent.
Statistical analysis
Mean levels of factor VIII, factor IX, factor XI,
VWF, and ﬁbrinogen according to 10-yr age
categories were compared between patients and
control women; for CRP, the median was used.
ABO blood group was dichotomized in blood
group non-O (A, B and AB) vs. O. Quartiles of
factor VIII, factor IX, factor XI, VWF, ﬁbrin-
ogen and CRP levels were deﬁned to assess a
dose–response relationship between levels and the
risk of MI, and risks were calculated relative to
the lowest stratum, the reference category. Odds
ratios (OR) were calculated as a measure of
relative risk with 95% conﬁdence intervals
(95% CI) and were derived from the logistic
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regression model. The odds ratios were adjusted
for the stratiﬁcation variables (age, index
year and area of residence) and putative con-
founders.
Results
Mean levels of factor VIII, factor IX, VWF and
ﬁbrinogen were higher in patients than in control
women, in contrast to factor XI levels, which did
not diﬀer between cases and controls (Table 1).
Factor VIII, factor IX, factor XI, VWF and
ﬁbrinogen levels increased with age. The mean
age at blood sampling was 48 yr (range 31–59) for
patients and 44 yr (range 22–59) for control
women. The median time between the index date
(date of MI in cases, or the matched date for
controls) and blood draw was 5 yr (range 2–9). As
expected, patients had a higher prevalence of
classical risk factors at the index date than control
women.
Table 2 shows that blood group non-O was
found more frequently among patients than among
control women (47% vs. 33%), and women with
blood group non-O had a 1.6 fold [95% conﬁdence
interval (CI) 1.1–2.3] increased risk of MI com-
pared with those with blood group O. Adjusted for
factor VIII levels, the OR for blood group non-O
vs. O became 1.3 (95% CI 0.9–1.9) and after
adjustment for VWF levels 1.2 (95% CI 0.9–1.8).
Mean factor VIII levels were lower in blood
group O carriers (100 IU/dL, 95% CI 96–104)
compared with blood group non-O carriers
(130 IU/dL, 95% CI 125–134), with 95% CI for
mean diﬀerence 24–36 IU/dL. Mean VWF levels
were lower in blood group O carriers (97 IU/dL,
95% CI 93–100) compared with blood group non-
O carriers (126 IU/dL, 95% CI 122–130), 95% CI
for mean diﬀerence 24–35 IU/dL. Factor VIII
levels >150 IU/dL were present in 32% of the
patients and 17% of the control women, and
increased the risk of MI more than twofold
compared with factor VIII levels below 100 IU/
dL. The ORs remained virtually unaﬀected after
adjustment for CRP, diabetes, hypertension, hyper-
cholesterolaemia and obesity. However, after addi-
tional adjustment for VWF levels, the ORs for both
categories of factor VIII levels 125–150 IU/dL and
‡150 IU/dL decreased to 1.3 (95% CI 0.7–2.3).
Von Willebrand factor levels >150 IU/dL were
present in 34% of the patients and 14% of the
control women, and increased the risk of MI 5.6-
fold (95% CI 3.0–10.4) compared with factor VWF
levels below 100 IU/dL. The odds ratio remained
high (OR 4.7; 95% CI 2.3–9.7) after adjustment for
the eﬀect of blood group, while the dose–response
relation persisted as well. Further adjustment for
factor VIII, smoking, hypertension, hypercholes-
terolaemia, diabetes and obesity did not aﬀect the
ORs.
Table 1. Characteristics of the patients with myocardial infarction and control
women, and mean levels of coagulation factors according to age categories
Patients
(n ¼ 200)
Control women
(n ¼ 626)
Mean
difference (95% CI)
Age, yr, mean (SD) 48.7 (6.1) 44.8 (8.4) 3.9 (2.4–4.9)
Range 31–59 22–59
Factor VIII:C (IU/dL) 133 111 22 (15–29)
18–29 yr 139 103 36 (5–66)
30–39 yr 123 107 16 (11–30)
40–49 yr 136 117 19 (10–28)
Von Willebrand
factor:ag (IU/dL)
134 107 26 (21–34)
18–29 yr 130 97 33 (5–62)
30–39 yr 131 102 29 (16–40)
40–49 yr 135 114 21 (13–30)
Factor IX:C (IU/dL) 132 120 12 (8–16)
18–29 yr 119 116 3 ()15 to 21)
30–39 yr 124 117 7 ()1 to 14)
40–49 yr 136 123 13 (7–19)
Factor XI:C (IU/dL) 114 113 1 ()4 to 6)
18–29 yr 107 102 5 ()11 to 22)
30–39 yr 105 103 2 ()5 to 9)
40–49 yr 114 113 1 ()4 to 6)
Fibrinogen (g/L) 3.53 3.20 0.33 (0.23–0.45)
18–29 yr 3.18 3.09 0.09 ()0.38 to 0.58)
30–39 yr 3.41 3.14 0.27 (0.05–0.48)
40–49 yr 3.59 3.27 0.32 (0.18–0.46)
C-reactive protein,
IQR (mg/L)
2.74
(0.76 to ‡10)
1.34
(0.50–4.97)
P < 0.011
Hypertension (%) 53 (27) 40 (6) 21 (15–26)
Diabetes (%) 10 (5) 10 (2) 3 (1–6)
Hypercholesterolaemia (%) 20 (10) 19 (3) 7 (1–10)
Obesity (%) 58 (29) 73 (12) 17 (11–23)
Smoking cigarettes (%) 164 (82) 267 (43) 39 (32–47)
1Mann–Whitney U-test.
IQR, interquartile range.
Table 2. Odds ratios for myocardial infarction for blood group non-O vs. O, for
categories of factor VIII:C and VWF:ag
Patients,
n (%)
Controls,
n (%)
Odds ratio1
(95% CI)
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Blood group
O 66 (33) 293 (47) 1 1 1
Non-O 134 (67) 333 (53) 1.6 (1.1–2.3) 1.3 (0.9–1.9)2 1.2 (0.9–1.8)4
Factor VIII:C (IU/dL)
<100 55 (27) 295 (47) 1 1 1
100–125 40 (20) 136 (22) 1.4 (0.8–2.5) 1.3 (0.7–2.3)3 1.1 (0.6–2.1)4
125–150 42 (21) 90 (14) 2.1 (1.2–3.6) 1.9 (1.1–3.4)3 1.3 (0.7–2.3)4
‡150 63 (32) 105 (17) 2.7 (1.6–4.6) 2.5 (1.4–4.2)3 1.3 (0.7–2.3)4
VWF:ag (IU/dL)
<100 50 (25) 310 (50) 1 1 1
100–125 50 (25) 141 (22) 2.4 (1.2–4.7) 2.4 (1.2–4.7)3 2.3 (1.2–4.6)2
125–150 32 (16) 85 (14) 3.3 (1.7–6.4) 3.2 (1.6–6.2)3 3.1 (1.6–6.2)2
‡150 68 (34) 90 (14) 5.6 (3.0–10.4) 5.2 (2.7–10)3 4.9 (2.4–10)2
1 ¼ Reference category.
1Adjusted for stratification variables (age, index year and area of residence).
2Adjusted for stratification variables and factor VIII:C levels.
3Adjusted for stratification variables and blood group.
4Adjusted for stratification variables and VWF:Ag levels.
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Table 3 shows the ORs for MI for diﬀerent
ﬁbrinogen and CRP categories. The OR for MI in
the highest quartile of CRP levels was 2.0 (95% CI
1.1–3.6) compared with those in the lowest quartile.
After adjustment for hypercholesterolaemia, diabe-
tes and BMI, the OR decreased to 1.0 (95% CI 0.5–
1.9).
Table 4 shows the risk of MI for various categ-
ories of factor IX levels. Adjustment for putative
confounders attenuated the ORs for MI from 3.6
(95% CI 1.8–6.7) to 2.6 (95% CI 1.3–5.4) in the
highest category with factor IX levels above
150 IU/dL, compared with women who had factor
IX levels below 100 IU/dL. Mean factor IX levels
were 134 IU/dL in oral contraceptive users com-
pared with 115 IU/dL in non-users (mean diﬀer-
ence 19 IU/dL, 95%CI 15 to 24). Adjustment for
factor VIII levels did not change the ORs. ORs for
categories with increasing factor XI levels were 1.1
(95% CI 0.8–1.7), 1.0 (95% CI 0.6–1.7), and 1.6
(95% CI 0.8–3.2) compared with the reference
category.
Discussion
In this study, we found that elevated levels of factor
VIII, factor IX and VWF, deﬁned as levels
>150 IU/dL compared with levels <100 IU/dL,
were associated with an increased risk of MI in
young women; the associations between these
coagulation factor levels and MI were dose-
dependent. The most pronounced relationship was
found between elevated VWF levels and MI with a
ﬁvefold increased risk. Blood group non-O was
associated with an 1.6-fold increased risk of MI
compared with blood group O. This can be
explained by the increased factor VIII and VWF
levels, because the eﬀect of blood group disap-
peared after adjustment for these factors. Although
entirely explained by VWF and FVIII, blood group
because of its high prevalence is an important
genetic risk factor for MI in agreement with earlier
results in women (32) and men (33). Conventional
risk factors predominantly explain the association
between elevated ﬁbrinogen and CRP levels and MI
in young women. Factor XI levels were not
associated with MI.
Von Willebrand factor
High VWF levels were not only associated with
arterial thrombosis (13, 34) but also with a history
of diabetes and hypertension (35, 36). Von Wille-
brand factor is essential in primary haemostasis: it
serves as the carrier protein of factor VIII and
protects factor VIII against proteolysis, and plays a
crucial role in platelet aggregation during thrombus
formation under ﬂow conditions. The large vari-
ation in plasma factor VIII levels is predominantly
modulated by blood group (which explains about
30% of the genetically determined variation of
VWF levels), and VWF [50% of high factor VIII
levels are associated with high VWF levels in
venous thrombosis (37)], and to a lesser extent by
other stimuli. Recently, linkage studies have shown
a functional eﬀect of ABO locus polymorphisms on
VWF and factor VIII levels (38, 39). Generally,
three mechanisms could explain the association of
high levels of VWF and MI: ﬁrst, its association
with high levels of factor VIII at sites of vascular
damage, promoting ﬁbrin formation; secondly, by
its primary action of promoting platelet aggrega-
tion at those sites; thirdly, while increased levels of
VWF may be a marker for endothelial damage
because of more extensive atherosclerosis in those
with MI (14). In addition, early increase of VWF
after unstable angina has been found to be a
predictor of adverse outcome (40). In venous
thrombosis, as we showed earlier, the ﬁrst mech-
anism is predominant, because after mutual
Table 3. Risk effect of categorized fibrinogen and C-reactive protein levels in
women with myocardial infarction and control women
Patients,
n (%)
Controls,
n (%)
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Fibrinogen4 (g/L)
<2.5 9 (5) 83 (13) 1 1
2.5–3.5 97 (49) 361 (58) 1.8 (1.2–2.7)1 1.6 (1.0–2.4)2
3.5–4.5 74 (37) 150 (24) 2.6 (1.5–4.5)1 2.1 (1.2–3.6)2
‡4.5 19 (10) 27 (4) 2.3 (0.8–6.6)1 1.5 (0.5–4.5)2
CRP (mg/L)
<0.50 23 (12) 86 (14) 1 1
0.50–1.34 41 (20) 215 (34) 0.7 (0.4–1.3)1 0.5 (0.3–1.0)3
1.34–4.97 79 (39) 211 (34) 1.4 (0.8–2.4)1 0.8 (0.5–1.5)3
‡4.97 57 (29) 114 (18) 2.0 (1.1–3.6)1 1.0 (0.5–1.9)3
1 ¼ Reference category.
1Adjustment for stratification variables (age, index year and area of residence).
2Adjustment for stratification variables (age, index year and area of residence) and
CRP.
3Adjustment for stratification variables (age, index year and area of residence),
hypercholesterolaemia, diabetes and BMI.
4Fibrinogen was missing in 1 patient and 5 control women.
Table 4. Odds ratios for myocardial infarction according to strata of factor IX:C
levels (in IU/dL)
Patients1,
n (%)
Control women,
n (%)
Odds ratio2
(95% CI)
Odds ratio3
(95% CI)
<100 18 (10) 133 (21) 1 1
100–125 59 (33) 237 (38) 1.7 (1.0–3.1) 1.6 (0.8–2.9)
125–150 61 (34) 187 (30) 2.2 (1.2–4.0) 1.3 (0.6–2.4)
‡150 41 (23) 69 (11) 3.5 (1.8–6.7) 2.6 (1.3–5.4)
1 ¼ Reference category.
1Women on oral anticoagulation therapy were excluded from the analysis (n ¼ 21).
2Adjusted for the stratification variables (age, index year and area of residence).
3Adjusted for stratification variables, hypertension, current smoking, obesity, family
history of CVD and oral contraceptive use.
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adjustment of factor VIII and VWF levels, the
eﬀect of VWF levels disappeared while an eﬀect of
factor VIII levels remained (1). In this study of MI,
we observed the opposite: after mutual adjustment,
VWF levels remained associated with risk, while
factor VIII levels did not.
Obviously, the association of non-O blood group
with risk cannot be the result of endothelial
damage, so we conclude that at least part of the
association between high levels of VWF and MI is
causal, and related to the eﬀect on platelet aggre-
gation. Apparently, secondary haemostasis plays a
less prominent role in the coronary vascular bed, as
opposed to the ﬁndings in venous thrombosis. The
larger eﬀect of antiplatelet agents in the prevention
of arterial thrombotic events than in the prevention
of venous thrombosis supports this view.
Factor VIII, factor IX and factor XI
High levels of factor VIII and IX were associated
with a more than twofold increased risk of MI in
contrast with high levels of factor XI. This suggests
that there is a role for secondary haemostasis in the
aetiology of coronary thrombosis, although less
pronounced than for platelet aggregation. This is in
line with the ﬁndings on the role of these procoag-
ulant factors on the opposite side of the coagula-
tion spectrum. Patients with haemophilia A and B
have a strongly reduced risk of MI (24, 41) and
carriers of haemophilia, with on average 50% of
the normal level of factor VIII or factor IX, are
moderately protected (42). Fully in line with our
ﬁndings of no eﬀect of elevated levels of factor XI,
severe hereditary deﬁciency of factor XI did not
protect against MI in a Jewish population (43).
C-reactive protein and fibrinogen
As factor VIII and ﬁbrinogen are acute-phase
proteins, that both rise in response to numerous
stimuli, we have used CRP as a marker of acute-
phase reaction. The inﬂuence of an acute-phase
response to the event itself on the coagulation
factors was minimized because blood samples
were drawn more than 212 yr after the event.
However, ongoing inﬂammatory processes related
to atherosclerosis could be expected to lead to
elevated levels of factor VIII. Adjustment for
CRP did not aﬀect the risk estimates of high
factor VIII levels. In our study, the association
between MI in young women and CRP levels was
completely explained by the presence of conven-
tional risk factors. Earlier observations in women
(44) men (27) and diabetics (45) showed reduction
in risk estimates for CRP after adjustment for
other cardiovascular risk factors.
Aspects of the study design
A strong aspect of our study is that we included
women in a nation-wide study, including all
university hospitals in the country and surrounding
regional centres. This is the largest study among
young women to date, and the inclusion of
consecutively diagnosed cases renders selection bias
unlikely. The blood samples were collected after the
event and, therefore, for each of the analyses the
possibility of post hoc changes on the coagulation
parameters should be carefully considered. This is
mainly so for factor VIII and VWF. However, the
association with ABO blood group phenotypes can
only be causal, and from this we have to built up
the interpretation of the results.
We cannot exclude an eﬀect of atherosclerotic
disease on procoagulant factors in this case–
control study, but did not ﬁnd an association
between the coagulation factors and the time that
had elapsed since the MI, indicating the absence
of acute eﬀects of the event. It should be noted
that this limitation would not even be solved by a
prospective study design with blood samples
taken prior to the MI, because patients with
more extensive atherosclerosis are at higher risk
of MI.
Conclusions
In the ﬁeld of determinants of the risk of MI in
young women, this study showed a conﬁrmation of
the role of elevated VWF, factor VIII and factor IX
levels. Based on recent literature, VWF could be an
important risk marker during multifactorial car-
diovascular risk factor intervention in the near
future (35, 36). These risk factors are dose-depend-
ent and their variability in plasma has a measurable
genetic component. Based on current data, we
conclude that these procoagulant factors are related
with both venous and arterial disorders. As these
entities have traditionally been considered diﬀerent
diseases, this is an important point and supports
the presence of common risk factors for venous and
arterial thrombosis (46).
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